Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

85.03 -2.62 (-2.99%)
Official Closing Price Updated: 4:10 PM EST, Jan 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,690,541
Open 86.11
Bid (Size) 85.05 (2)
Ask (Size) 85.18 (1)
Prev. Close 87.65
Today's Range 84.80 - 86.34
52wk Range 81.50 - 148.15
Shares Outstanding N/A
Dividend Yield 1.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors Look Back at 2024
The S&P 500 had a great year. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga

Performance

YTD
-2.85%
-2.85%
1 Month
-23.24%
-23.24%
3 Month
-27.80%
-27.80%
6 Month
-40.57%
-40.57%
1 Year
-20.08%
-20.08%

More News

Read More
President-Elect Trump Poses Challenge To U.S. Tech Sales
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Via Benzinga
Exposures Product Safety
Is Novo Nordisk an Undervalued Stock to Buy Now?
Via The Motley Fool
What's Going on With Novo Nordisk Stock?
Via The Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
3 Trends To Watch
Via Talk Markets
Topics Stocks / Equities
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Via Benzinga
4 Top Stocks to Buy in January
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Via Benzinga
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Via The Motley Fool
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Behind the Scenes of Novo Nordisk's Latest Options Trends
Via Benzinga
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
Via Chartmill
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Top Growth Stocks for 2025
Via The Motley Fool
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic
Via Benzinga
Prediction: This Will Be Amazon's Next Big Acquisition
Via The Motley Fool
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.